Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024 Successfully completed Phase 1, dose-ranging clinical pharmacology trial of intravenous GH002 in healthy volunteers Additional patents granted in Europe Cash, cash equivalents,... Read More